Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered NX-019 in Patients with Advanced, EGFR Mutant Cancer

NCT05514496 is registered in ClinicalTrials.gov with Nalo Therapeutics Inc. as lead sponsor.

NCT NCT05514496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05514496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered NX-019 in Patients with Advanced, EGFR Mutant Cancer
Lead sponsor
Nalo Therapeutics Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 5, 2022
Completion date
December 1, 2025
Enrollment
258 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutation-related tumors